Pharmafile Logo

News and Press Releases

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance. 10 March...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

Medidata Expands Partnership with The Menarini Group, Deploying Medidata’s Study Build AI Technology to Accelerate Global Oncology Pipeline

Fourteen-year collaboration enters a new phase as Menarini evolves its use of the Medidata Platform, combining established clinical workflows with AI to power its global oncology pipeline 9 March 2026...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026

Medidata
helpdesk@mdsol.com
350 Hudson Street New York, NY 10014 USA

European Commission approves AKEEGA (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall survival versus standard...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles 26 February 2026 -- Massachusetts, US...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 3, 2026

Curium Pharma
contactus@curiumpharma.com
Perceptive 55 Blue Sky Drive Burlington Massachusetts 01803 United States

Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening

• Drs Giulia Kennedy, Arnold Levine, John Sninsky, Martin Goldberg and Prof Tin Tin Su join SAB• Follows close of initial funding round with investment from Stephen Quake and Jay...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 2, 2026

Wisdom Bioscience
info@wisdombioscience.com

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3 Data highlight the potential of this first-in-class next-generation T-cell engager to expand the role...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 26, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

NICE Recommends TEPKINLY▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy

Epcoritamab can now be accessed as an option to treat relapsed or refractory follicular lymphoma in adults after 2 or more lines of systemic treatment, only if epcoritamab is stopped...

Category: Drug Discovery, Other, Pharmaceutical
Posted: February 23, 2026

AbbVie
AbbVie House Vanwall Business Park Vanwall Road Maidenhead Berkshire SL6 4UB

Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin at ESGO 2026

9 of 10 patients at the highest dose remained free from peritoneal recurrence at 24 months at the recommended dose 17 February 2026 -- Oslo, Norway -- Oncoinvent, a biotech...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 17, 2026

Oncoinvent
oncoinvent@oncoinvent.com
Gullhaugveien 7 0484 Oslo Norway

Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC)

17 February 2026 -- Oslo, Norway -- Lytix Biopharma AS, a clinical-stage immuno-oncology company, today announced the publication of a review article in the Journal of ImmunoTherapy of Cancer (JITC)....

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: February 17, 2026

Lytix Biopharma
post@lytixbiopharma.com
Sandakerveien 138, 0484 Oslo, Norway

Neogap secures SEK 87 million to advance clinical development of its personalised immunotherapy

11 February 2026 -- Solna, Sweden -- Neogap Therapeutics AB, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, has raised SEK 87 million in a financing round led...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 11, 2026

Neogap Therapeutics
info@neogap.se
Stiftelsen Cancercentrum Karolinska (CCK) Visionsgatan 56 171 64 Solna, Sweden

Moderna Receives MHRA Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1

The LP.8.1 vaccine is the first commercially licenced mRNA vaccine to be manufactured in the UK at the Moderna Innovation and Technology Centre in Oxfordshire The updated vaccines will be...

Category: Biotechnology, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: February 10, 2026

Moderna
info@modernatx.com
Global Headquarters 200 Technology Square Cambridge, MA 02139

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

Financing led by Investissement Québec with continued support from long-standing investors Plans include the acceleration of clinical development of breakthrough GPCR targeting treatments for patients. 10 February 2026 -- Montreal,...

Category: Drug Discovery, Other, Pharmaceutical
Posted: February 10, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

SPT Labtech and BellBrook Labs Introduce High-Throughput Screening Platform for Cancer Research

Automated workflow to be highlighted at SLAS 2026, 7-11 February, Boston Collaboration combines precision liquid handling technology with Transcreener ADP2 fluorescence polarization assay for screening of VPS4B ATPase inhibitors. 9...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 9, 2026

SPT Labtech
discover@sptlabtech.com
SPT Labtech Ltd. Melbourn Science Park Melbourn Hertfordshire SG8 6HB United Kingdom

ALTx Therapeutics launches into the Slingshot accelerator with £12.55 million of funding

Based on the pioneering work of British scientist Simon Boulton, ALTx leverages fundamental insights in cancer cell immortalisation to develop novel treatments for cancer Spinning out of The Francis Crick...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 5, 2026

Slingshot Therapeutics
info@slingshot-accelerator.co.uk

Johnson & Johnson receives CHMP positive opinion for AKEEGA (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen as a new standard...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG